Quick Answer
PDS Biotechnology Corp reported Total Assets of $30.49 million for the year ending 2025.
- PDS Biotechnology Corp showed a decrease of -32.8% in Total Assets from 2024 to 2025.
- This data is from PDS Biotechnology Corp's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $58.48 million | Q1 2016: $123.77 million | Q2 2016: $115.42 million | Q3 2016: $116.58 million | Q1 2017: $99.90 million | Q2 2017: $112.99 million | Q3 2017: $101.24 million | Q1 2018: $76.61 million | Q2 2018: $47.21 million | Q3 2018: $37.67 million | Q1 2019: $31.05 million | Q2 2019: $25.80 million | Q3 2019: $19.38 million | Q1 2020: $23.93 million | Q2 2020: $20.09 million | Q3 2020: $34.45 million | Q1 2021: $27.76 million | Q2 2021: $77.39 million | Q3 2021: $71.75 million | Q1 2022: $61.04 million | Q2 2022: $56.00 million | Q3 2022: $74.89 million | Q1 2023: $68.45 million | Q2 2023: $63.75 million | Q3 2023: $57.19 million | Q1 2024: $69.01 million | Q2 2024: $60.50 million | Q3 2024: $52.45 million | Q1 2025: $47.03 million | Q2 2025: $40.48 million | Q3 2025: $34.71 million.
- Over the full 12 years of available data (2014 to 2025), PDS Biotechnology Corp's Total Assets has grown by 81.0%.
- Historical annual values: Fiscal year 2025: $30.49 million | Fiscal year 2024: $45.36 million | Fiscal year 2023: $59.39 million | Fiscal year 2022: $77.01 million | Fiscal year 2021: $67.20 million | Fiscal year 2020: $30.89 million | Fiscal year 2019: $14.49 million | Fiscal year 2018: $164.4 thousand | Fiscal year 2017: $92.62 million | Fiscal year 2016: $110.91 million | Fiscal year 2015: $134.09 million | Fiscal year 2014: $16.85 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: